Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report

Authors

DOI:

https://doi.org/10.2340/actadv.v102.1378

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, et al. Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy. Int J Mol Sci 2017; 18: 2532.

https://doi.org/10.3390/ijms18122532

Wang M, Li F, Wang X, Wang X, Wang R, Yang Y, et al. Features and risk factors for paraneoplastic autoimmune multiorgan syndrome in 145 Chinese patients. Acta Derm Venereol 2020; 100: adv00312.

https://doi.org/10.2340/00015555-3673

Ouedraogo E, Gottlieb J, de Masson A, Lepelletier C, Jachiet M, Salle de Chou C, et al. Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults. J Am Acad Dermatol 2019; 80: 1544-1549.

https://doi.org/10.1016/j.jaad.2018.03.043

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29: 2062-2068.

https://doi.org/10.1038/leu.2015.212

Takahashi H, Kouno M, Nagao K, Wada N, Hata T, Nishimoto S, et al. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. J Clin Invest 2011; 121: 3677-3688.

https://doi.org/10.1172/JCI57379

McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet 2021; 398: 803-816.

https://doi.org/10.1016/S0140-6736(21)00438-4

Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014; 123: 3832-3842.

https://doi.org/10.1182/blood-2013-12-543736

Sarny S, Hucke M, El-Shabrawi Y. Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib. JAMA Ophthalmol 2018; 136: 1420-1422.

https://doi.org/10.1001/jamaophthalmol.2018.3789

James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep 2021; 22: 101104.

https://doi.org/10.1016/j.ajoc.2021.101104

Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med 2014; 370: 1820-1828.

https://doi.org/10.1056/NEJMra1204664

Zhao Y, OuYang G, Shi J, Luo Y, Tan Y, Yu J, et al. Salvage therapy with low-dose ruxolitinib leads to a significant improvement in bronchiolitis obliterans syndrome in patients with cGVHD after allogeneic hematopoietic stem cell transplantation. Front Pharmacol 2021; 12: 668825.

https://doi.org/10.3389/fphar.2021.668825

Kaurinovic M, Delli K, Jonk AE, Biswana A, Hazenberg CLE, Choi G, et al. Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic graft-versus-host disease and oral involvement. Clin Oral Investig 2022; 26: 4209-4216.

https://doi.org/10.1007/s00784-022-04393-1

Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.

https://doi.org/10.1016/S0140-6736(09)60237-3

Wang D, Liu Y, Lai X, Chen J, Cheng Q, Ma X, et al. Efficiency and toxicity of ruxolitinib as a salvage treatment for steroid-refractory chronic graft-versus-host disease. Front Immunol 2021; 12: 673636.

https://doi.org/10.3389/fimmu.2021.673636

Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol 2018; 93: 339-347.

https://doi.org/10.1002/ajh.24976

Downloads

Published

2022-06-09

How to Cite

Fan, B., & Wang, M. (2022). Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report. Acta Dermato-Venereologica, 102, adv00732. https://doi.org/10.2340/actadv.v102.1378

Issue

Section

Short Communication

Categories